Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pfizer posts better-than-expected Q4 results

(Sharecast News) - Pharmaceutical giant Pfizer reported better-than-expected quarterly earnings on Tuesday, driven by its cost-cutting programme aimed at an eventual return to profitability. The company reported a fourth-quarter net loss of $3.37bn, compared with net income of $5bn a year-earlier. Revenues fell 41% to $14.24bn - below consensus estimates of $14.37bn.

Pfizer said the US government returned fewer courses of its Covid Paxlovid drug than expected, leading to a $3.5bn revenue reversal for the return of about 6.5 million doses compared with a prior forecast of a $4.2bn based on the return of around 7.9 million courses at the end of 2023.

Revenues from Covid products, antiviral treatment Paxlovid and Covid vaccine Comirnaty, came in at $12.5bn for 2023. Pfizer makes the Comirnaty vaccine with German partner BioNTech.

The company has set a $4bn cost-cutting target and has set its sights on growing earnings through its cancer treatments.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

AstraZeneca makes progress with two breast cancer treatments
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
Insurer Beazley keeps guidance after solid Q1 premiums growth
(Sharecast News) - Insurance group Beazley said that first-quarter results were in line with guidance with insurance written premiums (IWP) growing at high single digits.
Blackstone ups bid for Hipgnosis with $1.57bn offer
(Sharecast News) - Music rights owner Hipgnosis said it it agreed terms on a £1.2bn takeover by private equity investor Blackstone, in the latest tit-for-tat battle with rival Concord.
Aukett Swanke flags delays to some contracts
(Sharecast News) - Smart buildings, architectural and design services specialist Aukett Swanke said in an update on Friday that, as outlined in its recent financial statements, it maintained a robust pipeline of interest, although a number of projects had been pushed back.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.